What Happens When You Stop Taking GLP-1 Medications

What the Largest Study Found

The Oxford/BMJ meta-analysis, published in The BMJ in January 2026, combined data from 37 studies involving 9,341 adults who stopped taking weight management medications. Participants had been on treatment for an average of 39 weeks before stopping, with an average follow-up of 32 weeks after.

The faster regain rate for newer GLP-1s compared to older medications and behavioral programs is notable. The study found this difference was independent of how much weight was initially lost, meaning it was not simply because GLP-1s produce more weight loss.

What the Individual Trials Show

The SURMOUNT-4 trial provides the most detailed picture for tirzepatide. After 36 weeks of treatment, 670 participants who had lost at least 10% of their body weight were randomized to either continue tirzepatide or switch to placebo for 52 additional weeks.

Participants who continued lost an additional 5.5% of body weight. Those who switched to placebo regained 14% over the same period. A follow-up analysis published in JAMA Internal Medicine found that 82% of those who stopped regained at least 25% of their lost weight.

For semaglutide, the STEP 1 extension study followed 327 participants for one year after stopping all treatment. They regained two-thirds of the weight they had lost during the 68-week treatment period. At one year after stopping, 48% still had clinically meaningful weight loss (5%+), down from 86% at the end of treatment.

Why Weight Regain Happens

Weight regain after stopping GLP-1 medications is not a personal failure. It is a biological response that research has documented extensively.

GLP-1 medications work by mimicking hormones that regulate appetite and satiety. When you stop taking them, those signals return to their pre-treatment state. Your brain gets the same hunger signals it was getting before treatment. The appetite suppression that made it easier to eat less disappears.

At the same time, your body has metabolic adaptations to the lower weight. Your resting metabolic rate is lower than it was at a higher weight (because you have less body mass to maintain). Ghrelin, the hormone that drives hunger, increases. Meanwhile, leptin levels drop, so your body gets weaker signals that you are full. These biological changes work against maintaining the lower weight.

This is the same biology that makes maintaining weight loss from dieting difficult. The medication was counteracting these forces. Without it, the forces are back.

Health Improvements Reverse Too

Weight regain is not the only thing that reverses. The Oxford/BMJ analysis found that improvements in HbA1c, fasting glucose, blood pressure, cholesterol, and triglycerides all trended back toward pre-treatment levels, with an estimated return to baseline within approximately 1.4 years of stopping.

The SURMOUNT-4 follow-up analysis showed a dose-response relationship between regain and health reversal:

Keeping even a portion of the weight off preserves some health benefits. Full regain means full reversal.

What Helps Maintain Weight After Stopping

The research is clear that stopping abruptly leads to significant regain. But there is evidence for strategies that slow or partially prevent it.

Exercise: The Strongest Evidence

A 2024 study published in eClinicalMedicine compared weight maintenance one year after stopping liraglutide (an older GLP-1), with and without exercise. The results were striking:

• Combination (exercise + liraglutide during treatment): 5.1 kg less regain than medication alone after one year off treatment
• Exercise alone during treatment: only 3.6 kg of regain in the year after stopping
• Medication alone: 9.6 kg of regain (roughly two-thirds of initial loss)
• The combination group was 7.2 times more likely to maintain 10%+ weight loss compared to the control group

Exercise during GLP-1 treatment appears to build a foundation that persists after the medication stops. Resistance training is particularly valuable because it preserves muscle mass, which supports metabolic rate.

Dose Reduction Instead of Full Stop

Emerging research suggests that reduced-frequency dosing (every 2 weeks instead of weekly) may maintain weight loss while lowering cost. A 2025 study in Obesity found that less frequent dosing helped maintain weight loss and metabolic improvements, though larger trials are needed. The SURMOUNT-MAINTAIN trial (expected completion May 2026) is studying whether a lower maintenance dose of tirzepatide can prevent regain.

Transition to Other Medications

A real-world study found that patients who transitioned to less expensive medications (metformin, topiramate, phentermine, or bupropion) after 12 months of GLP-1 therapy were able to maintain weight loss. This approach reduces cost while potentially preserving some of the benefit.

Protein and Resistance Training

Clinical guidelines recommend 1.2-1.6 grams of protein per kilogram of body weight daily, distributed across meals, combined with resistance training 2-5 days per week. These targets support lean mass preservation during treatment and may help maintain metabolic rate after stopping. A 2025 review confirmed that patients who exercised during GLP-1 therapy had less lean mass loss.

The Long-Term Treatment Question

The WHO issued its first-ever guideline on GLP-1 therapies for obesity in December 2025. It recognizes obesity as a "chronic, relapsing disease" and recommends GLP-1 therapies as long-term treatment.

The American Medical Association has classified obesity as a disease since 2013. The clinical consensus is that stopping GLP-1 therapy leads to disease recurrence, similar to how stopping blood pressure medication leads to elevated blood pressure.

This framing has practical implications for how you think about starting treatment:

• If you are paying $300/month, that is $3,600/year for potentially years of treatment. Cost becomes a long-term factor. See our cost comparison by access route for annual totals.
• Provider support matters over time. A provider that offers regular check-ins and dose adjustments is different from one that just writes the initial prescription.
• The evidence on exercise is worth paying attention to: building those habits during treatment provides real insurance against regain, whether you eventually stop the medication or reduce the dose.

No published clinical guidelines currently exist on how to safely discontinue GLP-1 therapy without weight rebound. Research on maintenance dosing, dose reduction, and combination strategies is ongoing.

The Bottom Line

The data is consistent across multiple studies: stopping GLP-1 medications leads to weight regain and reversal of health improvements for most people. Regain does not happen overnight, but the pattern is predictable.

This does not mean you should not start. It means you should go in with realistic expectations about the duration of treatment. Building exercise habits, maintaining adequate protein intake, and working with a provider who supports you long-term all improve the outcome, whether you stay on medication indefinitely or eventually transition to a lower dose or alternative approach.

Featured Programs

Programs with structured support beyond the initial prescription.

Sources

1. West S, Scragg J, Aveyard P, et al. Weight regain following cessation of medication for weight management. BMJ. 2026. DOI: 10.1136/bmj-2025-085304.
2. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024;331(1):38-48.
3. Aronne LJ, et al. SURMOUNT-4 post hoc analysis: weight regain and cardiometabolic reversal. JAMA Intern Med. 2025.
4. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension). Diabetes Obes Metab. 2022;24(8):1553-1564.
5. Jensen SBK, et al. Healthy weight loss maintenance with exercise, GLP-1 RA, or both combined. eClinicalMedicine. 2024;69:102475.
6. Wu A, et al. Less frequent dosing of GLP-1 RAs as a weight maintenance strategy. Obesity. 2025.
7. WHO. Global guideline on GLP-1 medicines in treating obesity. December 2025.